Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 2.67
BIIB's Cash to Debt is ranked higher than
67% of the 919 Companies
in the Global Biotechnology industry.

( Industry Median: 16.62 vs. BIIB: 2.67 )
BIIB' s 10-Year Cash to Debt Range
Min: 0.36   Max: No Debt
Current: 2.67

Equity to Asset 0.74
BIIB's Equity to Asset is ranked higher than
79% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. BIIB: 0.74 )
BIIB' s 10-Year Equity to Asset Range
Min: 0.54   Max: 0.87
Current: 0.74

0.54
0.87
Interest Coverage 78.86
BIIB's Interest Coverage is ranked higher than
58% of the 432 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. BIIB: 78.86 )
BIIB' s 10-Year Interest Coverage Range
Min: 2.3   Max: 9999.99
Current: 78.86

2.3
9999.99
F-Score: 8
Z-Score: 16.22
M-Score: -2.49
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 35.98
BIIB's Operating margin (%) is ranked higher than
96% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. BIIB: 35.98 )
BIIB' s 10-Year Operating margin (%) Range
Min: -128.05   Max: 52.91
Current: 35.98

-128.05
52.91
Net-margin (%) 25.64
BIIB's Net-margin (%) is ranked higher than
95% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -69.75 vs. BIIB: 25.64 )
BIIB' s 10-Year Net-margin (%) Range
Min: -128.85   Max: 36.64
Current: 25.64

-128.85
36.64
ROE (%) 24.68
BIIB's ROE (%) is ranked higher than
95% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -28.10 vs. BIIB: 24.68 )
BIIB' s 10-Year ROE (%) Range
Min: -21.44   Max: 31.98
Current: 24.68

-21.44
31.98
ROA (%) 18.10
BIIB's ROA (%) is ranked higher than
96% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -21.69 vs. BIIB: 18.10 )
BIIB' s 10-Year ROA (%) Range
Min: -15.14   Max: 24.62
Current: 18.1

-15.14
24.62
ROC (Joel Greenblatt) (%) 133.94
BIIB's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -217.20 vs. BIIB: 133.94 )
BIIB' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -62.79   Max: 211.79
Current: 133.94

-62.79
211.79
Revenue Growth (%) 16.30
BIIB's Revenue Growth (%) is ranked higher than
88% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. BIIB: 16.30 )
BIIB' s 10-Year Revenue Growth (%) Range
Min: -13.9   Max: 84.7
Current: 16.3

-13.9
84.7
EBITDA Growth (%) 26.20
BIIB's EBITDA Growth (%) is ranked higher than
94% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. BIIB: 26.20 )
BIIB' s 10-Year EBITDA Growth (%) Range
Min: -16.4   Max: 131
Current: 26.2

-16.4
131
EPS Growth (%) 25.60
BIIB's EPS Growth (%) is ranked higher than
92% of the 649 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. BIIB: 25.60 )
BIIB' s 10-Year EPS Growth (%) Range
Min: -66   Max: 205.2
Current: 25.6

-66
205.2
» BIIB's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

BIIB Guru Trades in Q3 2013

Pioneer Investments 1,774 sh (New)
Louis Moore Bacon 10,000 sh (+100%)
Mario Gabelli 3,310 sh (+81.87%)
John Hussman 75,000 sh (+50%)
Frank Sands 4,635,241 sh (+1.52%)
Ken Fisher 1,774 sh (+0.4%)
Vanguard Health Care Fund 1,451,300 sh (unchged)
Stanley Druckenmiller 91,500 sh (unchged)
Ken Heebner Sold Out
Murray Stahl 8,583 sh (-0.5%)
PRIMECAP Management 17,968,172 sh (-1.53%)
RS Investment Management 18,473 sh (-2.21%)
Jeremy Grantham 136,728 sh (-5.38%)
Bill Frels 1,125 sh (-13.46%)
Jim Simons 869,700 sh (-37.59%)
Ray Dalio 6,174 sh (-41.27%)
Steven Cohen 204,605 sh (-54.94%)
Paul Tudor Jones 1,500 sh (-60.53%)
Andreas Halvorsen 290,345 sh (-69.95%)
» More
Q4 2013

BIIB Guru Trades in Q4 2013

Ray Dalio 19,057 sh (+208.67%)
Steven Cohen 260,905 sh (+27.52%)
Paul Tudor Jones 1,767 sh (+17.8%)
Ken Fisher 2,038 sh (+14.88%)
Mario Gabelli 3,710 sh (+12.08%)
RS Investment Management 19,478 sh (+5.44%)
Frank Sands 4,754,160 sh (+2.57%)
Bill Frels 1,125 sh (unchged)
Stanley Druckenmiller 91,500 sh (unchged)
Louis Moore Bacon Sold Out
John Hussman Sold Out
Andreas Halvorsen Sold Out
Jeremy Grantham 136,231 sh (-0.36%)
Murray Stahl 8,532 sh (-0.59%)
PRIMECAP Management 17,777,602 sh (-1.06%)
Pioneer Investments 1,475 sh (-16.85%)
Jim Simons 542,338 sh (-37.64%)
Vanguard Health Care Fund 884,000 sh (-39.09%)
» More
Q1 2014

BIIB Guru Trades in Q1 2014

Joel Greenblatt 3,931 sh (New)
Caxton Associates 10,000 sh (New)
John Burbank 783 sh (New)
George Soros 7,500 sh (New)
Andreas Halvorsen 388,900 sh (New)
Ken Heebner 116,000 sh (New)
Ron Baron 6,089 sh (New)
Ken Fisher 18,266 sh (+796.27%)
Jeremy Grantham 476,999 sh (+250.14%)
Paul Tudor Jones 3,299 sh (+86.7%)
Frank Sands 4,873,017 sh (+2.5%)
Bill Frels 1,125 sh (unchged)
Jim Simons Sold Out
Ray Dalio Sold Out
Stanley Druckenmiller Sold Out
Murray Stahl 8,493 sh (-0.46%)
Steven Cohen 258,862 sh (-0.78%)
PRIMECAP Management 17,502,106 sh (-1.55%)
Mario Gabelli 3,585 sh (-3.37%)
RS Investment Management 17,671 sh (-9.28%)
Pioneer Investments 1,251 sh (-15.19%)
Vanguard Health Care Fund 599,400 sh (-32.19%)
» More
Q2 2014

BIIB Guru Trades in Q2 2014

Jim Simons 129,261 sh (New)
Stanley Druckenmiller 103,800 sh (New)
Louis Moore Bacon 32,500 sh (New)
Ken Fisher 88,885 sh (+386.61%)
Jeremy Grantham 857,799 sh (+79.83%)
Ron Baron 8,632 sh (+41.76%)
Mario Gabelli 4,175 sh (+16.46%)
Frank Sands 4,891,463 sh (+0.38%)
Bill Frels 1,125 sh (unchged)
Steven Cohen 7,600 sh (unchged)
Murray Stahl 8,493 sh (unchged)
Joel Greenblatt Sold Out
Ken Heebner Sold Out
John Burbank Sold Out
Andreas Halvorsen Sold Out
Caxton Associates Sold Out
George Soros Sold Out
PRIMECAP Management 17,258,311 sh (-1.39%)
Pioneer Investments 1,232 sh (-1.52%)
Vanguard Health Care Fund 559,700 sh (-6.62%)
RS Investment Management 16,250 sh (-8.04%)
Paul Tudor Jones 899 sh (-72.75%)
» More
» Details

Insider Trades

Latest Guru Trades with BIIB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-06-30 Sold Out 0.02%$274 - $320.13 $ 329.7610%0
George Soros 2014-06-30 Sold Out 0.02%$274 - $320.13 $ 329.7610%0
John Burbank 2014-06-30 Sold Out 0.01%$274 - $320.13 $ 329.7610%0
Ron Baron 2014-06-30 Add 41.76%$274 - $320.13 $ 329.7610%8632
Vanguard Health Care Fund 2014-03-31 Reduce -32.19%0.24%$273.518 - $351.94 $ 329.764%599400
Ray Dalio 2014-03-31 Sold Out 0.04%$273.518 - $351.94 $ 329.764%0
Joel Greenblatt 2014-03-31 New Buy0.02%$273.518 - $351.94 $ 329.764%3931
George Soros 2014-03-31 New Buy0.02%$273.518 - $351.94 $ 329.764%7500
John Burbank 2014-03-31 New Buy0.01%$273.518 - $351.94 $ 329.764%783
Ron Baron 2014-03-31 New Buy0.01%$273.518 - $351.94 $ 329.764%6089
John Hussman 2013-12-31 Sold Out 0.99%$223.85 - $295.88 $ 329.7628%0
Vanguard Health Care Fund 2013-12-31 Reduce -39.09%0.47%$223.85 - $295.88 $ 329.7628%884000
Ray Dalio 2013-12-31 Add 208.67%0.03%$223.85 - $295.88 $ 329.7628%19057
John Hussman 2013-09-30 Add 50%0.33%$206.53 - $248.13 $ 329.7648%75000
Ray Dalio 2013-09-30 Reduce -41.27%0.01%$206.53 - $248.13 $ 329.7648%6174
Mario Gabelli 2013-09-30 Add 81.87%$206.53 - $248.13 $ 329.7648%3310
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Biogen Idec Inc

Ken Fisher's Top Increases of the Second Quarter
CEO and CIO of Fisher Investments and regular Forbes contributor, Ken Fisher, had a pretty busy second quarter. Fisher purchased a total of 50 new stocks. His second quarter portfolio holds 558 stocks and is valued at over $47.56 billion. The following five stocks represent the five companies where Fisher made the largest increase in holdings during the second quarter. Read more...
Ken Fisher's Top Increases of the First Quarter
CEO and CIO of Fisher Investments, Ken Fisher, had a pretty busy first quarter. Fisher purchased a total of 57 new stocks. His first quarter portfolio holds 541 stocks and is valued at over $44.34 billion. The following five stocks represent the five companies where Fisher made the largest increase in holdings. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 36.60
BIIB's P/E(ttm) is ranked higher than
91% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. BIIB: 36.60 )
BIIB' s 10-Year P/E(ttm) Range
Min: 11.74   Max: 120.59
Current: 36.6

11.74
120.59
P/B 8.10
BIIB's P/B is ranked higher than
66% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 5.71 vs. BIIB: 8.10 )
BIIB' s 10-Year P/B Range
Min: 1.59   Max: 9.51
Current: 8.1

1.59
9.51
P/S 9.40
BIIB's P/S is ranked higher than
80% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 20.23 vs. BIIB: 9.40 )
BIIB' s 10-Year P/S Range
Min: 2.8   Max: 20.67
Current: 9.4

2.8
20.67
PFCF 33.30
BIIB's PFCF is ranked higher than
95% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. BIIB: 33.30 )
BIIB' s 10-Year PFCF Range
Min: 7.42   Max: 34.82
Current: 33.3

7.42
34.82
EV-to-EBIT 25.63
BIIB's EV-to-EBIT is ranked higher than
92% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. BIIB: 25.63 )
BIIB' s 10-Year EV-to-EBIT Range
Min: 8.3   Max: 79.3
Current: 25.63

8.3
79.3
PEG 1.82
BIIB's PEG is ranked higher than
98% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. BIIB: 1.82 )
BIIB' s 10-Year PEG Range
Min: 0.42   Max: 2.54
Current: 1.82

0.42
2.54
Shiller P/E 58.40
BIIB's Shiller P/E is ranked higher than
94% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. BIIB: 58.40 )
BIIB' s 10-Year Shiller P/E Range
Min: 30.09   Max: 114.6
Current: 58.4

30.09
114.6
Current Ratio 2.05
BIIB's Current Ratio is ranked higher than
61% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 3.97 vs. BIIB: 2.05 )
BIIB' s 10-Year Current Ratio Range
Min: 1.74   Max: 17.39
Current: 2.05

1.74
17.39
Quick Ratio 1.67
BIIB's Quick Ratio is ranked higher than
62% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 3.81 vs. BIIB: 1.67 )
BIIB' s 10-Year Quick Ratio Range
Min: 1.34   Max: 16.79
Current: 1.67

1.34
16.79

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 19.73
BIIB's Price/Tangible Book is ranked higher than
65% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 9.10 vs. BIIB: 19.73 )
BIIB' s 10-Year Price/Tangible Book Range
Min: 0.17   Max: 48.16
Current: 19.73

0.17
48.16
Price/DCF (Projected) 3.45
BIIB's Price/DCF (Projected) is ranked higher than
93% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. BIIB: 3.45 )
BIIB' s 10-Year Price/DCF (Projected) Range
Min: 0.65   Max: 25.99
Current: 3.45

0.65
25.99
Price/Median PS Value 1.21
BIIB's Price/Median PS Value is ranked higher than
80% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. BIIB: 1.21 )
BIIB' s 10-Year Price/Median PS Value Range
Min: 0.04   Max: 4.63
Current: 1.21

0.04
4.63
Price/Peter Lynch Fair Value 1.76
BIIB's Price/Peter Lynch Fair Value is ranked higher than
98% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. BIIB: 1.76 )
BIIB' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.44   Max: 20.5
Current: 1.76

0.44
20.5
Price/Graham Number 5.64
BIIB's Price/Graham Number is ranked higher than
88% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. BIIB: 5.64 )
BIIB' s 10-Year Price/Graham Number Range
Min: 0.43   Max: 21.27
Current: 5.64

0.43
21.27
Earnings Yield (Greenblatt) 3.90
BIIB's Earnings Yield (Greenblatt) is ranked higher than
72% of the 472 Companies
in the Global Biotechnology industry.

( Industry Median: 4.90 vs. BIIB: 3.90 )
BIIB' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.3   Max: 12
Current: 3.9

1.3
12
Forward Rate of Return (Yacktman) 21.54
BIIB's Forward Rate of Return (Yacktman) is ranked higher than
96% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: -10.76 vs. BIIB: 21.54 )
BIIB' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.3   Max: 53.6
Current: 21.54

-0.3
53.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, CELG, CMXHY » details
Traded in other countries:IDP.Germany
Biogen Idec Inc., was formed as a California corporation in 1985 and became a Delaware corporation in 1997. In 2003, the Company acquired Biogen, Inc. and changed its corporate name from IDEC Pharmaceuticals Corporation to Biogen Idec Inc. The Company is a global biotechnology company that discovers, develops, manufactures and markets therapies for the treatment of multiple sclerosis (MS) and other autoimmune disorders, neurodegenerative diseases and hemophilia. The Company also collaborates on the development and commercialization of RITUXAN and anti-CD20 product candidates for the treatment of non-Hodgkin's lymphoma and other conditions. The Company's marketed products include AVONEX; TYSABRI; RITUXAN; FAMPYRA; FUMADERM. AVONEX is one of the prescribed treatments in the world for relapsing forms of MS. MS is a progressive neurological disease in which the body loses the ability to transmit messages along nerve cells, leading to a loss of muscle control, paralysis and, in some cases, death. TYSABRI has advanced the treatment of MS patients with its established efficacy. TYSABRI is a monoclonal antibody approved in numerous countries as a monotherapy treatment for relapsing MS and also approved in the U.S. to treat Crohn's disease, an inflammatory disease of the intestines. RITUXAN is a prescribed monoclonal antibody therapeutic used to treat non-Hodgkin's lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia and two forms of ANCA-associated vasculitis. FAMPYRA is the first treatment that addresses the unmet medical need of walking improvement in adult patients with MS who have walking disability. FAMPYRA is a prolonged-release tablet formulation of the drug fampridine. FUMADERM is approved for the treatment of severe psoriasis in Germany. Psoriasis is a skin disease in which cells build up on the skin surface and form scales and red patches. The Company is facing competition from other biotechnology firms and large pharmaceutical companies. The Company is subject to various federal and state laws pertaining to health care 'fraud and abuse,' including anti-kickback laws and false claims laws.
» More Articles for BIIB

Headlines

Articles On GuruFocus.com
Baxter Will Remain Diversified and With Competitive Advantages Sep 02 2014 
Ken Fisher's Top Increaes of the Second Quarter Jul 28 2014 
Ken Fisher's Top Increases of the First Quarter Apr 22 2014 
Weekly 52-Week Highs Highlight: ORLY, LLL, BIIB, NVS Feb 09 2014 
Weekly CFO Sells Highlight: CSOD, UTX, MEMS, SBAC, BIIB Sep 22 2013 
PRIMECAP Trims Top Biotechs and More Aug 30 2013 
Edward Owens’ Vanguard Health Care Fund Does More Shedding than Adding in Third Quarter Nov 01 2012 
52-Week High Guru Stocks: BIIB, GE, BDX, IR, PFE Sep 24 2012 
Weekly Top Insider Sells: GOOG, FIS, ORCL, and BIIB Aug 06 2012 
Spectrum: Allos Acquisition Means Huge Upside Potential May 04 2012 


More From Other Websites
Olivier Danos Joins Biogen Idec as Senior Vice President, Gene Therapy Sep 23 2014
Most Big Cap 20 Stocks Near Entries, But Risks Exist Sep 22 2014
Gilead's (GILD) Zydelig Gets EU Clearance for Blood Cancer Sep 22 2014
Zacks Rank #1 Additions for Tuesday Sep 16 2014
Biogen/AbbVie Report Positive Data on MS Drug Zinbryta Sep 15 2014
Nasdaq Falls Hard, But Apple Resilient On iPhone Orders Sep 15 2014
3 Stocks Underperforming Today In The Drugs Industry Sep 15 2014
Gilead, Jazz, Salix Among Top 6 IBD 50 Drugmakers Sep 13 2014
Sanofi Reports Data on Multiple Sclerosis Drug Lemtrada Sep 12 2014
Biogen Reports Positive Two-Year Data on MS Drug Plegridy Sep 12 2014
Detailed Results from Biogen Idec and AbbVie’s Pivotal Phase 3 Decide Study Further Define the... Sep 12 2014
Stocks Show Modest Losses; Biotechs Pressured Again Sep 11 2014
Short Sellers Remain Vigilant Against Biotechs Sep 11 2014
Biogen Idec, Inc. Suddenly Struggling To Keep Up With The Biotech Joneses Sep 11 2014
New Data from ENDORSE Show Positive Results Continued over Five Years with TECFIDERA® (Dimethyl... Sep 11 2014
PLEGRIDY™ (Peginterferon Beta-1a) Two-Year Data Confirm Maintenance of Efficacy and Safety in... Sep 11 2014
Stocks Turn Higher After Soft Start; U.S. Silica Jumps Sep 10 2014
Receptos MS Drug Yields More Good Data; Stock Jumps Sep 10 2014
Biotech Stock Roundup: AbbVie Ties Up with Infinity, Keryx Slips on FDA Approval Sep 10 2014
New International Survey Finds MS Patients and Neurologists View Communication Positively, Yet... Sep 10 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK